https://www.reviewofoptometry.com/news/article/eye-drop-for-...
I've been following the development of this drug since before it was bought by Novartis.
I was expecting the average results to get better along with the median, but perhaps the dosage just wasn't high enough in this trial.
https://www.reviewofoptometry.com/news/article/eye-drop-for-...
I've been following the development of this drug since before it was bought by Novartis.
I was expecting the average results to get better along with the median, but perhaps the dosage just wasn't high enough in this trial.